Lauren Christine Harshman MD

Genitourinary Oncology, Hematologic Oncology

Assistant Professor, Medicine - Oncology, Dana-Farber Cancer Center, Harvard Medical School

450 Brookline AveDana 1230Boston, MA 02215
Phone+1 617-632-4524

Dr. Harshman is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Harshman's full profile Already have an account?

Education & Training

Stanford Health CareFellowship, Hematology and Medical Oncology, 2006 - 2009
Yale-New Haven Medical CenterResidency, Internal Medicine, 2003 - 2006
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2003

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2006 - Present
FL State Medical License 2023 - 2027
MA State Medical License 2012 - 2021
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2015, 2017
CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2015, 2017
CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2015, 2017

Clinical Trials

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
TERMINATED
PHASE1, PHASE2
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
COMPLETED
PHASE1
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy Start of enrollment: 2017 Apr 28
ACTIVE_NOT_RECRUITING
PHASE3

Publications & Presentations

PubMed

3 citations
Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase...
Matthew S Robertson, Yating Wang, SuChun Cheng, Hyesun Park, Shahar Glomski
La Radiologia Medica. 2025-01-01
48 citations
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3...
Mohamad E Allaf, Se-Eun Kim, Viraj Master, David F McDermott, Lauren C Harshman
The Lancet. Oncology. 2024-08-01
15 citations
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.
Atish D Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M Allaire, Jaqueline Marquez
Cancer Immunology Research. 2024-06-04

Journal Articles

Tumor Fraction in Cell-Free DNA as a Biomarker in Prostate Cancer
Heather A. Parsons, Atish D. Choudhury, Lauren C. Harshman, Daniel G. Stover, The Journal of Clinical Investigation
A Dose Finding Clinical Trial of Cabozantinib (XL184) Administered in Combination with Abiraterone Acetate in Metastatic Castration‐Resistant Prostate Cancer
Christopher Sweeney, Lauren C Harshman, Mark Pomerantz, Brandon Bernard, Atish D Choudhury, Philip W Kantoff, The Prostate

Lectures

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (E...
2019 ASCO Annual Meeting - 6/1/2019
PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrec...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
13th Multidisciplinary Management of Cancers: A Case-based Approach
Stanford Hospital & Clinic, Stanford, California - 3/9/2012

Press Mentions

The Combination of Pembrolizumab and Radium-223 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Atish ChouduryFebruary 26th, 2021
Activity of Cabozantinib in Advanced Non–Clear Cell Renal Cell CarcinomaMarch 15th, 2019
Cabozantinib Active Across Non-Clear Cell Kidney CancersMarch 6th, 2019